Published on 17 Nov 2021 on Benzinga via Yahoo Finance
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) has priced an underwritten public offering of 4.03 million at .75 per share and pre-funded warrants to purchase up to an aggregate of 3.27 million shares at $13.74 per pre-funded warrant.The offer price represents a discount of 5% from the last close price of $14.50 on Tuesday.The aggregate gross proceeds from this offering are expected to be approximately $100.3 million.Underwriters have an option to purchase up to an additional 1.09 million shares.The offering will close by November 19.Cowen and Guggenheim Securities are acting as joint book-running managers for the offering.EyePoint will use the proceeds to advance EYP-1901, support earlier stage pipeline development initiatives and general corporate purposes.Recently, the Company announced encouraging six-month interim data from the Phase 1 trial of EYP-1901 in wet age-related macular degeneration.Price Action: EYPT shares are up 3.20% at $14.50 during the premarket session on the last check Wednesday.
See more from Benzinga